Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 12, Issue 9, pp. 1874-1885
PubMed
Published By
Print ISSN
Online ISSN
History
- Received January 7, 2013
- Revision received June 21, 2013
- Accepted July 10, 2013
- Published first July 16, 2013.
Article Versions
- Previous version (July 16, 2013 - 14:20).
- Previous version (August 28, 2013 - 13:07).
- You are viewing the most recent version of this article.
Copyright & Usage
©2013 American Association for Cancer Research.
Author Information
- Andrew Stone1,
- Mark J. Cowley1,
- Fatima Valdes-Mora1,2,
- Rachael A. McCloy1,
- C. Marcelo Sergio1,
- David Gallego-Ortega1,2,
- C. Elizabeth Caldon1,2,
- Christopher J. Ormandy1,2,
- Andrew V. Biankin1,2,
- Julia M.W. Gee3,
- Robert I. Nicholson3,
- Cristin G. Print4,
- Susan J. Clark1,2, and
- Elizabeth A. Musgrove1,2
- Authors' Affiliations: 1The Kinghorn Cancer Centre & Cancer Research Division, Garvan Institute of Medical Research; 2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, St Vincent's Hospital, Sydney, New South Wales, Australia; 3Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, Wales, United Kingdom; and 4Bioinformatics Institute and School of Medical Sciences, University of Auckland, Auckland, New Zealand
- Corresponding Author:
Andrew Stone, Garvan Institute of Medical Research, L9 TKCC, 370 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia. Phone: 61-424618528; Fax: 61-293555869; E-mail: a.stone{at}garvan.org.au
September 2013
Volume 12, Issue 9
Volume 12, Issue 9
BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
Jump to section
Advertisement